Interactions Involving Cyclosporine A., Interleukin-6, and Epstein-Barr Virus Lead to the Promotion of B-Cell Lymphoproliferative Disease

Leukemia and Lymphoma

Volumn 21, Issue 42130, 1996, Pages 379-390

  Tanner, Jerome E ^a,b   Alfierp, Caroline ^b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

cyclosporine A; disease; Epstein Barr; IL 6; immunosuppression; lymphoproliferative; tumors

Indexed keywords

COMPLEMENT COMPONENT C3D RECEPTOR; CYCLOSPORIN A; GROWTH FACTOR; INTERLEUKIN 6; VIRUS GLYCOPROTEIN;

ARTICLE; B LYMPHOCYTE; CELL IMMORTALIZATION; CONTROLLED STUDY; CYTOLYSIS; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MOLECULAR INTERACTION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; B-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; CELLS, CULTURED; COCARCINOGENESIS; CYCLOSPORINE; GENE EXPRESSION REGULATION; GENES, VIRAL; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; LYMPHOCYTE SUBSETS; LYMPHOMA; LYMPHOPROLIFERATIVE DISORDERS; MICE; MICE, NUDE; MONOCYTES; NEOPLASM PROTEINS; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION; TUMOR VIRUS INFECTIONS; VIRAL PROTEINS; VIRUS ACTIVATION;

EID: 0029939829     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428199609093435     Document Type: Article

References (77)

1. Greiner T C, Medieros L J, Jaffe E. Non-Hodgkin's lymphoma. Cancer 1994; 75: 370 – 380
2. Epstein M A. Virus particles in cultures of lymphoblasts from Burkitt's lymphoma. Lancet 1964; 702 – 703
3. Henle W, Henle G. Epstein-Barr virus and infectious mononucleosis. N. Engl. J. Med 1973; 288: 263 – 264
4. Pope J H, Home M K, Scott W. Transformation of fetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int. J. Cancer 1968; 3: 857 – 866
5. Peterson B. The role of transplantation in non-Hodgkin's lymphoma. J. Clin. Oncol 1994; 12: 2524 – 2526
6. Rabkin C S, Davesa S S, Zahm S H, Gail M H. Increasing incidence of non-Hodgkin's lymphoma. Sem. Oncol 1994; 30: 286 – 296
7. Penn I. Tumors of the immunocompromised patient. Ann. Rev. Med 1988; 39: 63 – 74
8. Thomas J A, Allday M L, Crawford D H. Epstein-Barr virus associated lymphoproliferative disorders in immunocompromised individuals. Adv. Cancer Res 1991; 57: 129 – 280
9. Savoie A, Perpete C, Carpentier L, Joncas L, Alfteri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994; 83: 2715 – 2722
10. Ho M, Miller G, Atchison R W, Breinig M K, Drummer J S, Andiman W, Starzl T E, Eastman R, Griffith B P, Hardesty R L, Bhanson H T, Hakala T R, Rosenthal J T. Epstein-Barr virus infections and DNA hybridization studies in post-transplant lymphoma and lymphoproliferative lesions: the role of primary infections. J. Infect. Dis 1985; 152: 876 – 886
11. Poplack D G, Magrath I T, Kun L E, Pizzo P A. Leukemia and lymphomas of childhood. Cancer: principles & practice of oncology. 4th edition, T V DeVita, S Hellman, S A Rosenberg. J. B. Lippincott, Philadelphia 1992; 1792 – 1818
12. Cotran R S. Diseases of white cells, lymph nodes, and spleen. Pathologic basis of disease, 5th edition, R S Cotran, V Kumar, S C Robbins. W. B. Saunders, Philadelphia 1994; 629 – 647
13. Ludwig C V, Gencik M, Shipman R. Multistep transformation in low grade lymphoproliferative disease. Ann. Oncol 1993; 4: 825 – 830
14. Purtilo D T, Strobach R S, Okano M, Davis J R. Epstein-Barr virus-associated lymphoproliferative disorders. Lab. Invest 1992; 67: 5 – 23
15. Klein G. Viral latency and transformation: the strategy of Epstein-Barr virus. Cell 1989; 58: 5 – 7
16. Kieff E, Liebowitz D, Knipe D. Epstein-Barr Virus and its replication. Fundamental Virology 2nd edition, B Fields. Raven Press, New York 1990; 897 – 928
17. Kaye K M, Izumi K M, Kieff E. Epstein-Barr virus latent membrane protein is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 1993; 90: 9150 – 9154
18. Cohen J I, Wang F, Mannick J, Kieff E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl Acad. Sci. USA 1989; 86: 9558 – 9562
19. Swaminathan S, Tomkinson B, Kieff E. Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro. Proc. Natl. Acad. Sci. USA 1991; 88: 1546 – 1550
20. Tomkinson B, Kieff E. Use of a second site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation. J. Virol 1993; 66: 2893 – 2903
21. Longnecker R, Miller C L, Miao X.-Q, Tomkinson B, Kieff E. The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro. LMP2A is therefore nonessential. J. Virol 1992; 66: 6461 – 6469
22. Wang F, Gregory C D, Rowe M, Rickinson A B, Wang D, Birkenbach M, Kieff E. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc. Natl. Acad. Sci. USA 1987; 84: 3452 – 3456
23. Wang F, Tsang S.-F, Kurilla M G, Cohen J L, Kieff E. Epstein-Barr nuclear antigen 2 transactivates latent membrane protein LMP1. J. Virol 1990; 64: 3407 – 3416
24. Liebowitz D, Kopan R, Fuchs E, Sample J, Kieff E. An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes. Mol. Cell Biol 1987; 7: 2299 – 2308
25. Mosialos G, Birkenbach M, Yalamachill R, Van Arsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signalling proteins for the tumor necrosis factor receptor family. Cell 1995; 80: 389 – 399
26. Sugden B. An intricate route to immortality. Cell 1989; 57: 5 – 7
27. Wang D, Liebowitz D, Kieff E. Epstein-Barr virus latent membrane protein alters the human B phenotype: deletion of the amino terminus abolishes activity. J. Virol 1988; 62: 2337 – 2346
28. Wang D, Liebowitz D, Kieff E. An Epstein-Barr virus latent membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985; 43: 831 – 840
29. Tosato G, Tanner J, Jones K D, Revel M, Pike S E. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J. Virol 1990; 64: 3033 – 41
30. Tanner J E, Goldman N D, Tosato G. Biochemical and biological analysis of human interleukin 6 expressed in rodent and primate cells. Cytokine 1990; 2: 363 – 374
31. Van Snick J. Interleukin-6: an overview. Ann. Rev Immunol 1990; 8: 253 – 278
32. Marrone G, Ciliberto G, Oliviero S, Arcone R, Dente L, Content L, Cortese R. Recombinant interleukin 6 regulates the transcriptional activation of a set of human acute phase genes. J. Biol. Chem 1988; 3: 12554 – 12558
33. Tanner J E, Tosato G. Regulation of B-cell growth and immunoglobulin gene transcription by interleukin-6. Blood 1992; 79: 452 – 459
34. Tosato G, Pike S. Interferon-beta 2/interleukin 6 is a costimulant for human T lymphocytes. J. Immunol 1988; 141: 1556 – 1562
35. Ikebuchi K, Wong G G, Clark S C, Ihle J N, Hirai Y, Ogawa M. Interleukin 6 enhancement of interleukin 3-de-pendent proliferation of multipotential hemopoietic progenitors. Proc. Natl. Acad. Sci. USA 1987; 84: 9035 – 9039
36. Freeman G J, Freedman A S, Rabinowe S N, Segil J M, Horowitz K, Rosen K, Whitman J F, Nadler L M. Interleukin 6 gene expression in normal and neoplastic B cells. J. Clin. Invest 1989; 82: 1512 – 1518
37. Yoshizaki K, Marsuda N, Nishimoto N, Kirtani T, Taeho K, Nakahata T, Kawai H, Togoh T, Komori S, Hirano T, Kishimoto T. Pathologic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989; 74: 1360 – 1367
38. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Nakahata T, Kawai H, Togho T, Komori T, Kishimoto S, Hirano T, Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1989; 332: 83 – 85
39. Miles S A, Rezai A R, Salazar-Gonzalez J F, Vander M, Myeden R H, Stevens D M, Logan R T, Mitsuyama T, Taga T, Hirano T, Kishimoto T, Martinez-Maza O. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc. Natl. Acad. Sci. USA 1990; 87: 4068 – 4072
40. Taga T, Kawanski K, Hardy R R, Hirano T, Kishimoto T. Receptors for B cell stimulatory factor 2: quantitation, specificity, distribution, and regulation of their expression. J. Exp. Med 1987; 166: 967 – 981
41. Tosato G, Seamon K B, Goldman N D, Segal P B, May L T. Identification of a monocyte-derived human B cell growth factor as interferon beta 2 (BSF-1, IL-6). Science 1987; 239: 502 – 504
42. Rickinson A B, Murray R J, Brooks J, Griffin H, Moss D J, Masucci M G. T cell recognition of Epstein-Barr virus associated lymphomas. Cancer Surveys 1992; 13: 53 – 80
43. Tanner I E, Tosato G. Impairment of natural killer cell function by IL-6 increases lymphoblastoid cell tumorigenicity in vivo. J. Clin. Invest 1991; 88: 239 – 248
44. Scala G, Quinto I, Ruocco M R, Arcucci A, Mallardo M, Caretto P, Formi G, Venuta S. Expression of exogenous interleukin-6 gene in human Epstein-Barr virus B cells confers growth advantage and in vivo tumorigenicity. J. Exp. Med 1990; 172: 61 – 68
45. Ruscetti F W, Palladino M A. Transforming growth factor-beta and the immune system. Progress in Growth Factor Res 1991; 3: 159 – 175
46. Trinchieri G. Biology of natural killer cells. Adv. Immunol 1989; 47: 187 – 376
47. McCormick K J, Giovannella B C, Klein G, Nilsson K, Stehlin J S. Diploid human lymphoblastoid and Burkitt's lymphoma cell lines: susceptibility to murine NK cells and heterotransplantation to nude mice. Int. J. Cancer 1981; 28: 445 – 458
48. Reynolds C W, Rotaldo J R. Nature and physiology of natural effector cells. Immunopathology, J Oppenheim, E Shevach. Oxford Press, New York 1990; 336 – 349
49. Scheid C, Young R, McDermott R, Fitzsimmons L, Scarffe J H, Stern P P. Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. Cancer Immunol. Immunotherapy 1994; 38: 119 – 126
50. Keisslig R, Klein G, Pross H, Wigzell W. Natural killer cells in the mouse. II cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of natural killer cells. Eur. J. Immunol 1975; 5: 117 – 121
51. Urban J L, Shepard H M, Rotstein J L, Sugarman B J, Schreiber H. Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc. Natl. Acad. Sci. USA 1986; 83: 5233 – 5237
52. Schindler R, Manculla J, Endres S, Ghorbani R, Clark S C, Dinarello C A. Correlations and interactions in the production of interleukin 6 (IL-6), IL-1 and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75: 40 – 47
53. Tosato G, Jones K, Breinig M K, McWilliams P, McKnight J. Interleukin-6 production in posttransplant lymphoproliferative disease. J. Clin. Invest 1993; 91: 2806 – 2814
54. Sigal N H, Dumont F J. Cyclosporin A., FK-506, and ripamycin: pharmacologic probes of lymphocyte signal transduction. Ann. Rev. Immunol 1992; 10: 519 – 560
55. Calne R Y, Rolles K, White D J. G, Thiru S, Evans D B, Henderson R, Hamilton D L, Boone N, McMaster P, Gibby O, Williams R. Cyclosporine A in clinical organ grafting. Transplant. Proc 1979; 13: 349 – 358
56. Ho M, Jaffe R, Miller G, Breinig M K, Drummer J S, Makowka L, Atchison R W, Karrer F, Nalesnik M A, Starzl T E. The frequency of EBV infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988; 45: 719 – 727
57. Merlino C, Giaccino F, Segoloni G, Negro Ponzi A. Epstein-Barr virus infection and immunoglobulin abnormalities in renal transplant recipients. Minerva Urilogica e Nefrologica 1992; 44: 143 – 146
58. Fric M, Hartmann A, Kehrl H U, Pfeifer U, Herberhold C. Regression of cerebral post-transplantation lymphoma under cyclosporine A reduction. Clinical Science 1990; 68: 1189 – 1194
59. Muraguchi A, Butler J L, Kehrl J H, Falkoff R J. M, Fauci A. Selective suppression of an early step in human B cell activation by cyclosporin. J. Exp. Med 1983; 158: 690 – 702
60. Hannam-Harris A C, Taylor D S, Nowell P C. Cyclosporin A directly inhibits B cell activation by more than a single step mechanism. J. Leuk. Biol 1985; 38: 231 – 239
61. Walz G, Zanker B, Melton L B, Suthanthiran M, Strom T B. Possible association of the immunosuppressive and B cell lymphoma promoting properties of cyclosporine. Transplantation 1990; 49: 191 – 194
62. Cen H, Williams P A, McWilliams H P, Breinig M C, Ho M, McKnight J L. C. Evidence for restricted Epstein-Barr Virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood 1993; 81: 1393 – 1403
63. Katz B Z, Saini U. Presence of the diffuse early antigen of Epstein-Barr virus in lymphomas and lymphoproliferative disorders. Am. J. Path 1992; 140: 1247 – 1254
64. Katz B Z, Raab-Traub N, Miller G. Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases. J. Infect. Dis 1989; 160: 589 – 598
65. Kibutani H, Taga T, Akira S, Kishi H, Miki Y, Saiki O, Yamamura Y, Kishimoto T. Effect of B cell differentiation factor (BCDF) on biosynthesis and secretion of immunoglobulin molecules in human B cell lines. J. Immunol 1985; 134: 990 – 995
66. Tanner J, Weis J, Fearon D, Whang Y, Kieff E. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping and endocytosis. Cell 1987; 50: 203 – 213
67. Tedder T F, Zhou L.-J, Engel P. The CD19/21 signal transduction complex of B lymphocytes. Immunol. Today 1994; 15: 437 – 442
68. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson K C, Ritz J, Shapiro R S, Rickinson A, Kieff E, Cohen J. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N. Engl. J. Med 1989; 321: 1080 – 1085
69. Yao Q Y, Rickinson A B, Gaston J S. H, Epstein M A. In vitro analysis of the Epstein-Barr virus: host balance in long term renal allograft recipients. Int. J. Cancer 1985; 35: 62 – 66
70. Hanto D W, Frizzera G, Gajl-Peczalska K J, Sakamoto K, Purtilo D T, Balfour H H, Simmons R L, Najarian K J. Epstein-Barr virus induced B-cell lymphoma after renal transplantation. N. Engl. J. Med 1982; 306: 913 – 918
71. Pirsch J D, Stratta R J, Sallinger H W, Hafez G K, d'Alessandro A M, Kalayoglu M, Belzer F O. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. Am. J. Med 1989; 86: 241 – 244
72. Rochford R, Mosier D E. Differential Epstein-Barr virus gene expression in B cell subset recovered from lymphomas in SOD mice after transplantation of human peripheral blood lymphocytes. J. Virol 1995; 69: 150 – 155
73. Gosselin J, Flamand L, D'Addario M, Hiscott J, Menezes J. Infection of peripheral blood mononuclear cells by herpes simplex and Epstein-Barr viruses, differential induction of IL-6 and tumor necrosis factor-alpha. J. Clin. Invest 1992; 89: 1849 – 1856
74. Revoltella R P, Vigneti E, Fruscalzo A, Park M, Ragona G, Rocchi G, Calef E. Epstein-Barr virus DNA sequences in precursor monocyte-macrophage cell lines established from the bone marrow of children with maturation defects of haematopoiesis. J. Gen. Virol 1989; 70: 1203 – 1215
75. Pettersson T, Metsarinne K, Teppo A.-M, Fyrquist F. Immunoreactive interleukin-6 in serum of patients with B-lympho-proliferative diseases. J. Intern. Med 1992; 232: 439 – 442
76. Birx D, Redfield R B, Tencer K, Fowler A, Burke D S, Tosato G. Induction of interleukin-6 during human immunodeficiency virus infection. Blood 1990; 76: 2303 – 2310
77. Breen E C, Rezai A R, Nakajima K, Beall G N, Mitsuyasu R T, Hirano T, Kishimoto T, Martinez-Maza O. Infection with HIV is associated with elevated IL-6 levels and production. J. Immunol 1990; 144: 480 – 484